Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) has been given a consensus rating of “Buy” by the nine analysts that are currently covering the firm, MarketBeat reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $59.25.
A number of research analysts have recently issued reports on the company. Oppenheimer dropped their price objective on Jasper Therapeutics from $80.00 to $65.00 and set an “outperform” rating on the stock in a research note on Thursday, May 15th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. Finally, UBS Group dropped their price objective on Jasper Therapeutics from $38.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th.
Get Our Latest Report on Jasper Therapeutics
Institutional Inflows and Outflows
Jasper Therapeutics Stock Performance
Jasper Therapeutics stock opened at $5.49 on Wednesday. The firm has a 50 day moving average price of $5.17 and a two-hundred day moving average price of $7.48. Jasper Therapeutics has a 52-week low of $3.13 and a 52-week high of $26.05. The firm has a market cap of $82.46 million, a price-to-earnings ratio of -1.05 and a beta of 2.72.
Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.24). As a group, equities research analysts predict that Jasper Therapeutics will post -4.47 EPS for the current fiscal year.
About Jasper Therapeutics
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
See Also
- Five stocks we like better than Jasper Therapeutics
- High Flyers: 3 Natural Gas Stocks for March 2022
- EA Just Caught a Monster Upgrade: Bullish Breakout Ahead?
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 Stocks Hitting All-Time Highs With More Room to Run
- Overbought Stocks Explained: Should You Trade Them?
- QuantumScape Soars 30%: What Drove the Next-Gen EV Stock’s Rally
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.